ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Conference activity picks up, with the big one – ASCO – at the end of the month.
AACR approaches, along with ASCO abstract titles.
While Sutro shows why it’s shelved luvelta-T.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.